ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2020

Abstract Number: 1945

Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients with Giant Cell Arteritis

Hussein Baalbaki1, Darya Jalaledin2, Catherine Lachance2 and Jean-Paul Makhzoum3, 1Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, 2Universite de Montreal, Montreal, QC, Canada, 3Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2020

Keywords: Eye Disorders, giant cell arteritis, risk factors, Vasculitis

Session Information

Date: Monday, November 9, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Permanent vision loss (PVL) is a feared complication and a leading cause of morbidity in Giant Cell Arteritis (GCA). Multiple risk factors for ocular involvement have been identified with variable consistency, including older age, male sex, presence of cardio-vascular risk factors, transient ischemic symptoms, jaw claudication and thrombocytosis. The objective of this study is to describe visual manifestations and identify risk factors that predict ocular involvement in patients with GCA.

Methods: The retrospective database, CAPHECO-GCA (Characteristics, Phenotype, Evolution and Complications of patients with GCA at Hopital du Sacre-Coeur de Montreal) was used to collect data between January 1st, 2000 and December 31st, 2019. The presence of GCA was based on the treating physician’s diagnosis and confirmed retrospectively by a separate GCA expert. Descriptive statistics comparing patients with and without visual symptoms and PVL were performed. Funding for the creation of the CAPHECO-GCA database was provided by CanVasc (Canadian Network for Research on Vasculitides).

Results: A total of 100 patients with GCA were included. Of these, 95 patients met the 1990 ACR classification criteria for GCA, and 53 patients had visual symptoms. Visual symptoms included blurred vision (30% of patients), diplopia (16% of patients), amaurosis fugax (14% of patients) and blindness (19% of patients). Out of the 19 patients with blindness, 16 did not recuperate and had PVL. Patients with PVL were older (79,2 ± 6,7 vs 74,2 ± 7,6 years; p = 0,008), more likely to have coronary artery disease (31% vs 10%; p = 0,018) and peripheral artery disease (19% vs 5%; p = 0,044) than patients without PVL. However, patients with PVL were less likely to have other cranial symptoms (81% vs 96%; p = 0,019), mainly headaches (64% vs 92%; p= 0,003). A total of 58 patients underwent ophthalmologic examination: 10 patients had anterior ischemic optic neuropathy, 3 patients had central retinal artery occlusion, 1 patient had branch retinal artery occlusion and 3 patients had cranial nerve palsy. Risk factors associated with an abnormal ophthalmologic examination were the same as for PVL, but patients were also more likely to have diabetes (29% vs 7%; p = 0,026) and less likely to have constitutional symptoms (53% vs 80%; p = 0,033). Presence of visual symptoms was associated with a lower mean C-reactive protein level (73,7 ± 59,3 vs 104,3 ± 80,3 mg/L; p = 0,035). There was no statistically significant difference for sex, prior eye disease, delay to presentation, polymyalgia rheumatica, abnormal temporal artery on physical examination, extra-cranial large vessel vasculitis and platelet count.

Conclusion: Patients with GCA and PVL and/or abnormal ophthalmologic examination were older and more likely to have baseline diabetes, coronary artery disease and peripheral artery disease. A predisposing vascular vulnerability might therefore increase the risk of ocular involvement in GCA.


Disclosure: H. Baalbaki, None; D. Jalaledin, None; C. Lachance, None; J. Makhzoum, None.

To cite this abstract in AMA style:

Baalbaki H, Jalaledin D, Lachance C, Makhzoum J. Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients with Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/characterization-of-visual-manifestations-and-identification-of-risk-factors-for-permanent-vision-loss-in-patients-with-giant-cell-arteritis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-visual-manifestations-and-identification-of-risk-factors-for-permanent-vision-loss-in-patients-with-giant-cell-arteritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology